Literature DB >> 24673454

Impaired proplatelet formation in immune thrombocytopenia: a novel mechanism contributing to decreased platelet count.

Paola R Lev1, Matías Grodzielski, Nora P Goette, Ana C Glembotsky, Yesica R Espasandin, Marta S Pierdominici, Geraldine Contrufo, Verónica S Montero, Luciana Ferrari, Felisa C Molinas, Paula G Heller, Rosana F Marta.   

Abstract

The pathophysiological mechanisms contributing to the decreased platelet count in immune thrombocytopenia (ITP) are not entirely understood. Here, we investigated the key step of proplatelet formation (PPF) by studying the effect of ITP plasma in thrombopoiesis. Normal cord blood-derived mature megakaryocytes were cultured in the presence of recalcified plasma from ITP patients, and PPF was evaluated by microscopic analysis. Patient samples induced a dose-dependent inhibition in PPF, as well as decreased complexity of proplatelet architecture. Although slightly increased, plasma-induced megakaryocyte apoptosis was not related to PPF impairment. Purified IgG reproduced the inhibitory effect, while platelet-adsorbed plasma induced its reversion, suggesting the involvement of auto-antibodies in the inhibition of thrombopoiesis. Impaired PPF, induced by ITP plasmas bearing anti-GPIIb-IIIa antibodies, was related to their ability to interfere with the normal function of this integrin, as assessed by megakaryocyte PAC-1 binding and β3 integrin phosphorylation while the presence of anti-glycoprotein Ia-IIa auto-antibodies was associated with loss of normal inhibition of PPF induced by type I collagen. In conclusion, abnormal thrombopoiesis comprising decreased PPF and morphological changes in proplatelet structure are induced by patient samples, unveiling new mechanisms contributing to decreased platelet count in ITP.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  auto-antibodies; immune thrombocytopenia; platelets; proplatelets; thrombopoiesis

Mesh:

Substances:

Year:  2014        PMID: 24673454     DOI: 10.1111/bjh.12832

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  18 in total

1.  Immunodiagnosis of platelet activation in immune thrombocytopenia through scFv antibodies cognate to activated IIb3 integrins.

Authors:  Preeti Bhoria; Neelam Varma; Pankaj Malhotra; Subhash Varma; Manni Luthra-Guptasarma
Journal:  MAbs       Date:  2015-08-24       Impact factor: 5.857

2.  Comparative study of IgG binding to megakaryocytes in immune and myelodysplastic thrombocytopenic patients.

Authors:  Doaa I Elzaeem; Esmat A El Sharkawi; Eman M Zaki; Ayman G Ghobrial; Aliaa S Abd El-Fatah; Waleed M Abd El-Hamed
Journal:  Ann Hematol       Date:  2021-05-13       Impact factor: 3.673

3.  Immune thrombocytopenia: antiplatelet autoantibodies inhibit proplatelet formation by megakaryocytes and impair platelet production in vitro.

Authors:  Muna Iraqi; Jose Perdomo; Feng Yan; Philip Y-I Choi; Beng H Chong
Journal:  Haematologica       Date:  2015-02-14       Impact factor: 9.941

4.  Platelet autoantibodies in the bone marrow of patients with immune thrombocytopenia.

Authors:  Sabrina Shrestha; Ishac Nazy; James W Smith; John G Kelton; Donald M Arnold
Journal:  Blood Adv       Date:  2020-07-14

5.  Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells.

Authors:  Jose Perdomo; Feng Yan; Halina H L Leung; Beng H Chong
Journal:  J Vis Exp       Date:  2017-12-27       Impact factor: 1.355

6.  Antibody binding to megakaryocytes in vivo in patients with immune thrombocytopenia.

Authors:  Donald M Arnold; Ishac Nazi; Lisa J Toltl; Catherine Ross; Nikola Ivetic; James W Smith; Yang Liu; John G Kelton
Journal:  Eur J Haematol       Date:  2015-03-13       Impact factor: 2.997

7.  Platelet Apoptosis in Adult Immune Thrombocytopenia: Insights into the Mechanism of Damage Triggered by Auto-Antibodies.

Authors:  Nora P Goette; Ana C Glembotsky; Paola R Lev; Matías Grodzielski; Geraldine Contrufo; Marta S Pierdominici; Yesica R Espasandin; Dardo Riveros; Alejandro J García; Felisa C Molinas; Paula G Heller; Rosana F Marta
Journal:  PLoS One       Date:  2016-08-05       Impact factor: 3.240

Review 8.  A Review of Romiplostim Mechanism of Action and Clinical Applicability.

Authors:  James B Bussel; Gerald Soff; Adriana Balduzzi; Nichola Cooper; Tatiana Lawrence; John W Semple
Journal:  Drug Des Devel Ther       Date:  2021-05-26       Impact factor: 4.162

9.  Treatment of 5 dogs with immune-mediated thrombocytopenia using Romiplostim.

Authors:  Barbara Kohn; Gürkan Bal; Aleksandra Chirek; Sina Rehbein; Abdulgabar Salama
Journal:  BMC Vet Res       Date:  2016-06-10       Impact factor: 2.741

Review 10.  Role of romiplostim in splenectomized and nonsplenectomized patients with immune thrombocytopenia.

Authors:  Jose Perdomo
Journal:  Immunotargets Ther       Date:  2016-02-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.